Although the current PD1/PD-L1 blocking antibody approved by the FDA shows significant therapeutic effects, especially in patients with melanoma and non-small cell lung cancer, these antibodies lack tumor-specific selectivity. The gene discussed is CD274; the disease is non-small cell lung carcinoma.